Paper39477136
Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes.
Fujita M and 5 others. Int J Pharm, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes. Papers, record 39477136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39477136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Piroxicam | Major topic |
| Solubility | Major topic |
| Thermodynamics | Major topic |
| Propranolol | |
| Tetracaine | |
| Drug Liberation | |
| Chemistry, Pharmaceutical | |
| Crystallization | |
| Polymers | |
| Anti-Inflammatory Agents, Non-Steroidal | |
| Models, Chemical |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942863 | Kinetic Model for Describing the Spring Effect and Incomplete Dissolution in Low-Solubility Drug Formulations Based on the Quality-by-Design (QbD) Approach. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942863 | PubMed |
| 42039300 | Advanced oral drug delivery systems: Current challenges and emerging technologies. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42039300 | PubMed |
| 41900829 | Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41900829 | PubMed |
| 41840256 | Polymer-Surfactant Stabilized Amorphous Nanosuspension of Pazopanib: Box-Behnken Optimization and In-vivo Evaluation. | AAPS PharmSciTech | 2026 | https://conductscience.org/library/papers/41840256 | PubMed |
| 41800360 | Multicomponent Oxicam-Metformin Salts: Toward a Strategy for Enhancing Solubility and Stability. | Cryst Growth Des | 2026 | https://conductscience.org/library/papers/41800360 | PubMed |
| 40586556 | Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems. | Mol Pharm | 2025 | https://conductscience.org/library/papers/40586556 | PubMed |
| 39818700 | Reactivity of Olanzapine and Tricyclic Antidepressants on the Protective Effects of Trolox on Lipid Peroxidation Evaluated Using Fluorescence Anisotropy, Electron Paramagnetic Resonance Spectrometry, and Thermal Analysis. | ACS Chem Neurosci | 2025 | https://conductscience.org/library/papers/39818700 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39477136
GET https://conductscience.org/api/papers/v1/39477136/authors